📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk. (2023)

First Author: Davies C

Attributed to: CANNABIDIOL AS A NOVEL THERAPEUTIC AGENT FOR PATIENTS AT ULTRA HIGH-RISK OF PSYCHOSIS: AN EXPERIMENTAL MEDICINE APPROACH funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/schizbullopen/sgad022

PubMed Identifier: 39145348

Publication URI: http://europepmc.org/abstract/MED/39145348

Type: Journal Article/Review

Volume: 4

Parent Publication: Schizophrenia bulletin open

Issue: 1

ISSN: 2632-7899